Please ensure Javascript is enabled for purposes of website accessibility
Inicio > Productos > Anticuerpos > Biosimilares

Anti-Human CD19 & PD-L1 & 4-1BB/TNFRSF9/CD137 & CD3 epsilon Multispecific Reference Antibody (Emfizatamab, RUO) (HB996096)

Anti-Human CD19 & PD-L1 & 4-1BB/TNFRSF9/CD137 & CD3 epsilon Multispecific Reference Antibody (Emfizatamab, RUO)
Anti-Human CD19 & PD-L1 & 4-1BB/TNFRSF9/CD137 & CD3 epsilon Multispecific Reference Antibody (Emfizatamab, RUO)
Anti-Human CD19 & PD-L1 & 4-1BB/TNFRSF9/CD137 & CD3 epsilon Multispecific Reference Antibody (Emfizatamab, RUO)
Anti-Human CD19 & PD-L1 & 4-1BB/TNFRSF9/CD137 & CD3 epsilon Multispecific Reference Antibody (Emfizatamab, RUO)
Anti-Human CD19 & PD-L1 & 4-1BB/TNFRSF9/CD137 & CD3 epsilon Multispecific Reference Antibody (Emfizatamab, RUO)
Anti-Human CD19 & PD-L1 & 4-1BB/TNFRSF9/CD137 & CD3 epsilon Multispecific Reference Antibody (Emfizatamab, RUO)
Precio(USD):
Especificación:
  • 100ug
  • 1mg
  • 5mg
  • 10mg
  • 25mg
  • 50mg
  • 100mg
Número:
Contáctenos
  • Vista general

  • Imágenes

  • Referencias

  • Datasheet

  • SDS

Vista general
Número de catálogoHB996096
Descripción
Emfizatamab (HB996096) is a research-grade recombinant antibody targeting CD19. Produced in mammalian cells with native-like glycosylation.
Highlights
  • ●Research Grade — For PK/PD studies, assay development, and ADA research.
  • ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactividad de especiesHuman
AplicacionesELISA, Bioactivity: FCM, Functional assay, Research in vivo, WB
ClonalidadMonoclonal
Isotipo(scFv-kappa-heavy)-G1_L-kappa-(scFv-heavy-kappa)-(scFv-heavy-kappa)
Aplicaciones probadas WB
Objetivo B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, CD152, CTLA-4, CTLA4, Cytotoxic T-lymphocyte protein 4, Cytotoxic T-lymphocyte-associated antigen 4, 4-1BB ligand receptor, CD137, CDw137, ILA, T-cell antigen 4-1BB homolog, T-cell antigen ILA, TNFRSF9, Tumor necrosis factor receptor superfamily member 9, CD3E, CD3e, T-cell surface antigen T3/Leu-4 epsilon chain, T-cell surface glycoprotein CD3 epsilon chain, T3E
Nivel de endotoxinas < 10 EU/mg
Pureza >95% as determined by SDS-PAGE.
Purificación Protein A/G purified from cell culture supernatant.
Número de acceso P15391 & Q9NZQ7 & Q07011 & P07766
Forma Liquid
Buffer de almacenamiento 0.01M PBS pH 7.4.

Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.

Información de uso del producto
Aplicación Dilución
WB 1:500-1:2000
Estabilidad y almacenamiento Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativosGNC038, GNC-038, GNC038, 2559704-23-1
FondoEmfizatamab is an anti-CD19/CD3E/TNFRSF9/PD-L1 monoclonal antibody.
Nota For research use only. Not suitable for clinical or therapeutic use.
Isotype Control Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507)
Imágenes
  • Anti-Human CD19 & PD-L1 & 4-1BB/TNFRSF9/CD137 & CD3 epsilon Multispecific Reference Antibody (Emfizatamab, RUO)

    SDS-PAGE

    SDS-PAGE for Research Grade Emfizatamab.

  • Anti-Human CD19 & PD-L1 & 4-1BB/TNFRSF9/CD137 & CD3 epsilon Multispecific Reference Antibody (Emfizatamab, RUO)

    Bioactivity

    Detects recombinant CD137 (Catalog No: HC336011) in indirect ELISA.

  • Anti-Human CD19 & PD-L1 & 4-1BB/TNFRSF9/CD137 & CD3 epsilon Multispecific Reference Antibody (Emfizatamab, RUO)

    Western blot

    Western blot analysis was performed using anti-CD3E monoclonal antibody at 1ug/mL on various samples.
    Lane 1: recombinant human CD3E (Catalog No: HY057021)

Referencias
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recomendación

Contáctenos para cotizaciones personalizadas, solicitudes en masa y cualquier otro problema.

Correo: [email protected]

Lista de distribuidores